Melanoma — TNM

AJCC 8th edition (2017), pathological — cutaneous melanoma
T — primary tumour (Breslow thickness / ulceration)
N — regional nodes / in-transit disease
M — distant metastasis

About this score

When to use

Assigns the AJCC 8th-edition pathological stage of cutaneous melanoma. ⁦[1, 2]⁩

Pearls and pitfalls

• T1 is now split at 0.8 mm, mitotic rate was removed from T staging, N categories were expanded for microsatellite and in-transit disease, and M1d (central nervous system) was added. ⁦[1]⁩
• The changes rest on a database of more than 46,000 patients from 10 centres worldwide. ⁦[1]⁩
• This tool uses the pathological stage table; the clinical stage table differs, and the stage III sub-groups are intricate. ⁦[3]⁩
Summarised from the numbered sources under Evidence. Check the source before relying on a statement.
Evidence
[1] Original publication
Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the AJCC eighth-edition cancer staging manual. T1 was split at 0.8 mm, mitotic rate was removed from T staging, N categories were expanded for microsatellites/in-transit disease, and M1d (CNS) was added; stage III was resolved into IIIA–IIID.
CA: A Cancer Journal for Clinicians, 2017
Open source
[2] Guideline
Amin MB, Edge SB, Greene FL, et al., eds. AJCC Cancer Staging Manual, 8th edition (print manual, no PubMed record).
Springer, 2017
[3] Note on this tool
This tool uses the pathological stage table; the clinical stage table differs. The stage III sub-groups are intricate — confirm against the manual.
Last reviewed: 2026-10
Report an error in this calculator
MedScore is an educational and clinical decision-support tool. It does not provide a diagnosis, a treatment, or a drug-dosing recommendation, and it does not replace clinical judgement or local guidelines. Confirm every result against the original source before acting on it. The treating clinician remains responsible for all decisions.
Support the developer
MedScore is free on the web and made by a medical student. If it helps you, you can support its development.
Support MedScore